| 貨號 | 規(guī)格 | 價格 | 上海 | 北京 | 武漢 | 南京 | 購買數(shù)量 |
|---|---|---|---|---|---|---|---|
S80870-1mg |
99.0% | ￥232.00 | 8 | - | - | - |
|
S80870-5mg |
≥99% | ￥432.00 | 貨期：2-3天 | - | - | - |
|
S80870-10mg |
99.0% | ￥800.00 | 8 | - | - | - |
|
S80870-25mg |
≥99% | ￥1520.00 | 貨期：2-3天 | - | - | - |
|
S80870-50mg |
99.0% | ￥2560.00 | 2 | - | - | - |
|
S80870-100mg |
≥99% | ￥4400.00 | 貨期：2-3天 | - | - | - |
|
(E)-Daporinad (FK866) is an effective inhibitor of nicotinamide phosphoribosyltransferase (NMPRTase; Nampt) with an IC50 of 0.09 nM.
| 產(chǎn)品描述： | (E)-Daporinad (FK866) is an effective inhibitor of nicotinamide phosphoribosyltransferase (NMPRTase; Nampt) with an IC50 of 0.09 nM. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶點： | IC50: 0.09 nM (NMPRTase) | ||||||||||||||||||||
| 體內(nèi)研究： | (E)-Daporinad (FK866) (30 mg/kg, i.p.) decreases the tumor burden in CB17-SCID mice, and the tumor tissue demonstrates a significant decrease in ERK phosphorylation and proteolytic cleavage of LC3 | ||||||||||||||||||||
| 參考文獻： | 1. Cea M, et al. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood. 2012 Oct 25;120(17):3519-29. 2. Magnone M, et al. NAD+ levels control Ca2+ store replenishment and mitogen-induced increase of cytosolic Ca2+ by Cyclic ADP-ribose-dependent TRPM2 channel gating in human T lymphocytes. J Biol Chem. 2012 Jun 15;287(25):21067-81. 3. Thakur BK, et al. Inhibition of NAMPT pathway by FK866 activates the function of p53 in HEK293T cells. Biochem Biophys Res Commun. 2012 Aug 3;424(3):371-7. | ||||||||||||||||||||
| 溶解性： | DMSO : ≥ 50 mg/mL (127.71 mM) H2O : 1 mg/mL (2.55 mM; Need ultrasonic) | ||||||||||||||||||||
| 保存條件： | -20℃ | ||||||||||||||||||||
| 配置溶液濃度參考： |
|
||||||||||||||||||||
| 注意： | 部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
滬公網(wǎng)安備 31011702002021號
危險品化學(xué)品經(jīng)營許可證（不帶存儲）
營業(yè)執(zhí)照(三證合一)
北京